Anaplastic lymphoma kinase gene mutation

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
3 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Kinase inhibitor 3 substances
Phase III: 1 Phase I (Other): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • F. Hoffmann-La Roche AG Commercial
    ALECTINIB; ALECTINIB HYDROCHLORIDE; CRIZOTINIB
    2023-506859-13-00 4 countries 2014 n=51
    Ended

Phase I (Other)

1 trial
  • Celgene Corp. Commercial
    IMP not specified
    2023-506094-35-00 3 countries 2021 n=112
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celgene Corp. Commercial 1 Phase I (Other) 0
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
New trials by year
2021
1
← All indication landscapes